Fennec Pharmaceuticals (FENC) CFO exercises 10,000 stock options at $2.45

Rhea-AI Filing Summary

Fennec Pharmaceuticals Inc. reported an insider transaction by its Chief Financial Officer, Robert Andrade. On 01/15/2026, he exercised 10,000 stock options with an exercise price of $2.45 per share, acquiring 10,000 common shares.

Following the transaction, Andrade directly beneficially owned 201,100 common shares and held 826,567 stock options that remained outstanding. The shares were acquired through the exercise of an option contract with a strike price of $2.45 and an expiration date of July 5, 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Andrade Robert

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NC 27709

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares(1)	01/15/2026		M		10,000	A	$2.45	201,100	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options(1)	$2.45	01/15/2026		M			10,000	07/05/2016	07/05/2026	Options	10,000	$2.45	826,567	D

Explanation of Responses:

1. Shares acquired through the exercise of an option contract with strike price of $2.45 and an expiration date of July 5, 2026.

	/s/ Robert Andrade	01/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Fennec Pharmaceuticals (FENC) disclose?

The company disclosed that its Chief Financial Officer, Robert Andrade, exercised 10,000 stock options at an exercise price of $2.45 per share and acquired 10,000 common shares on 01/15/2026.

Who is the insider involved in the latest FENC Form 4 filing?

The insider is Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals Inc., who is listed as an officer and the sole reporting person on the Form 4.

How many Fennec Pharmaceuticals common shares does the CFO own after the transaction?

After the reported transaction, Chief Financial Officer Robert Andrade beneficially owned 201,100 common shares of Fennec Pharmaceuticals Inc. directly.

How many Fennec stock options does the CFO hold after exercising options?

Following the option exercise, Chief Financial Officer Robert Andrade held 826,567 stock options beneficially owned directly, according to the Form 4.

What were the key terms of the exercised Fennec Pharmaceuticals stock options?

The exercised stock options covered 10,000 shares with a $2.45 strike price per share and an expiration date of July 5, 2026, as noted in the explanation of responses.

Was the Fennec Pharmaceuticals insider transaction a purchase or sale of shares?

The transaction reported was an exercise of stock options (transaction code M), resulting in the acquisition of 10,000 common shares rather than an open-market sale.